ReviewWorld journal of microbiology & biotechnology2025
Recent advances in metabolic engineering of Escherichia coli for riboflavin biosynthesis.
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Bacillus subtilis cell factories for nutraceuticals production.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Escherichia coli has emerged as a promising microbial platform for industrial riboflavin (RF) biosynthesis, enabled by systematic metabolic engineering of its well-characterized genetic system. This minireview synthesizes key strategies for enhancing RF production, focusing on: (i) Precursor optimization through reinforced pentose phosphate pathway flux (elevating ribulose-5-phosphate) and deregulated purine biosynthesis (boosting GTP availability); (ii) Pathway engineering via rib operon overexpression coupled with feedback inhibition relief through ribF modulation and FMN riboswitch deletion; (iii) Competitive flux minimization by redirecting carbon from acetate formation and catabolic side-reactions; and (iv) Cellular robustness enhancement through NADPH/ATP cofactor balancing and stress tolerance engineering. Complementary bioreactor parameter control including defined media formulations, temperature profiling, and dynamic pH/dissolved oxygen regulation has proven critical for translating laboratory-scale genetic improvements to high-titer production. Recent advances in CRISPR-based genome editing, multi-omics-guided pathway optimization, and antibiotic-free plasmid stabilization demonstrate E. coli's growing viability as a sustainable RF cell factory, with future progress hinging on integrated systems metabolic engineering approaches.
Indexed as
Identifiers
40999135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.